openPR Logo
Press release

Duchenne Muscular Dystrophy (DMD) Market Size Expected to Hit USD 2.1 billion by 2031, Driven by Robust 4.7% CAGR: AMR

06-09-2023 01:00 PM CET | Health & Medicine

Press release from: Allied Market Research (AMR)

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy Market

Allied Market Research has published a study report with the title Duchenne Muscular Dystrophy (DMD) Market Size was Valued at USD 1.3 billion in 2021 and is Projected to Garner USD 2.1 billion by 2031, registering a CAGR of 4.7% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

๐‚๐จ๐ฏ๐ข๐-๐Ÿ๐Ÿ— ๐’๐œ๐ž๐ง๐š๐ซ๐ข๐จ

โ€ข The outbreak of the Covid-19 pandemic had a negative impact on the global Duchenne muscular dystrophy market, owing to implementation of the global lockdown which led to temporary closure of many clinics, especially in the initial period.
โ€ข However, throughout the pandemic, despite the recommendations to maintain social distance, many individuals treated their illnesses via self-medication or other unconventional methods owing to their concern of contracting COVID during the lockdown.

๐–๐ก๐š๐ญ ๐š๐ซ๐ž ๐ญ๐ก๐ž ๐Ÿ๐š๐œ๐ญ๐จ๐ซ๐ฌ ๐๐ซ๐ข๐ฏ๐ข๐ง๐  ๐ญ๐ก๐ž ๐ƒ๐ฎ๐œ๐ก๐ž๐ง๐ง๐ž ๐Œ๐ฎ๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐ƒ๐ฒ๐ฌ๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ ๐Œ๐š๐ซ๐ค๐ž๐ญ?

Rise in the incidence of the Duchenne muscular dystrophy (DMD) and surge in need for better healthcare services drive the growth of the global Duchenne muscular dystrophy market. However, inflated cost of treatments for Duchenne muscular dystrophy restricts the market growth. On the other hand, increase in government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and rise in demand for innovative treatments for Duchenne muscular dystrophy present new opportunities in the coming years.

๐†๐ž๐ญ ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐๐ƒ๐… ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐†๐ซ๐š๐ฉ๐ก๐ฌ ๐š๐ง๐ ๐…๐ข๐ ๐ฎ๐ซ๐ž๐ฌ ๐‡๐ž๐ซ๐ž:
https://www.alliedmarketresearch.com/request-sample/16015

๐“๐จ๐ฉ ๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ ๐Ž๐Ÿ ๐ƒ๐ฎ๐œ๐ก๐ž๐ง๐ง๐ž ๐Œ๐ฎ๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐ƒ๐ฒ๐ฌ๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ (๐ƒ๐Œ๐ƒ)

โ€ข F Hoffmann-La Roche AG
โ€ข FibroGen, Inc
โ€ข GlaxoSmithKline plc
โ€ข Italfarmaco S.p.A.
โ€ข Nippon Shinyaku Co., Ltd
โ€ข Pfizer Inc.
โ€ข PTC Therapeutics
โ€ข Santhera Pharmaceuticals Inc
โ€ข Sarepta therapeutics
โ€ข Wave life sciences ltd.
โ€ข ABBOTT LABORATORIES

๐ƒ๐ฎ๐œ๐ก๐ž๐ง๐ง๐ž ๐Œ๐ฎ๐ฌ๐œ๐ฎ๐ฅ๐š๐ซ ๐ƒ๐ฒ๐ฌ๐ญ๐ซ๐จ๐ฉ๐ก๐ฒ (๐ƒ๐Œ๐ƒ) ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐’๐ข๐ณ๐ž ๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ญ๐ข๐จ๐ง: -

Based on therapeutic area, the molecular-based therapies segment held the highest market share in 2021, accounting for around three-fifths of the global Duchenne muscular dystrophy market, and is estimated to maintain its leadership status throughout the forecast period. In addition, the same segment is projected to manifest the highest CAGR of 5.0% from 2022 to 2031, owing to R & D activities for exon skipping drugs, strong product pipeline and significant product launch by key players. The report also discusses steroid therapy segment.

Based on distribution channel, the hospital pharmacies segment accounted for the largest share in 2021, contributing to more than three-fifths of the global Duchenne muscular dystrophy market, and is projected to maintain its lead position during the forecast period. This is owing to significant rise in the number of diagnosis through hospitals. However, the drug store & retail pharmacies segment is expected to portray the largest CAGR of 5.4% from 2022 to 2031, owing to the rise in the approval of drugs and their availability in drug store & retail pharmacies.

Based on region, North America held the highest market share in terms of revenue in 2021, accounting for more than half of the global Duchenne muscular dystrophy market, and is likely to dominate the market during the forecast period. This is owing to technological advancements in Duchenne muscular dystrophy treatment and presence of key players & robust hospital infrastructure in the region.

However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.9% from 2022 to 2031. This is owing to rise in cases of Duchenne muscular dystrophy, approval of drugs, development of healthcare infrastructure, and increase in investments projects in the region.

๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž ๐ญ๐ก๐ž ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:
https://www.alliedmarketresearch.com/purchase-enquiry/16015

Our Market Research Solution Provides You Answer to Below Mentioned Question:

โ€ข Which are the driving factors responsible for the growth of market?
โ€ข Which are the roadblock factors of this market?
โ€ข What are the new opportunities, by which market will grow in coming years?
โ€ข What are the trends of this market?
โ€ข Which are main factors responsible for new product launch?
โ€ข How big is the global & regional market in terms of revenue, sales and production?
โ€ข How far will the market grow in forecast period in terms of revenue, sales and production?
โ€ข Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
โ€ข How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
โ€ข Which region has more opportunities?

By Region Outlook

โ€ข North America
(U.S., Canada, Mexico)
โ€ข Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
โ€ข Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
โ€ข LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:
David Correa
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Duchenne Muscular Dystrophy (DMD) Market Size Expected to Hit USD 2.1 billion by 2031, Driven by Robust 4.7% CAGR: AMR here

News-ID: 3083384 • Views: โ€ฆ

More Releases from Allied Market Research (AMR)

Digital Pathology Market is Rising Rapidly Up to USD 17.91 Billion by 2030 | CAGR Of 9.3
Digital Pathology Market is Rising Rapidly Up to USD 17.91 Billion by 2030 | CAG โ€ฆ
Use of digital pathology in disease diagnosis, rise in the trend of digitalization in the medical sector, ease of consultation, and growth in diagnostic services in remote regions drive the growth of the global digital pathology market. On the other hand, lack of reimbursement policies and high cost of digital pathology solutions restrain the growth to some extent. However, increase in potential of digital pathology is projected to create numerousโ€ฆ
Audiology Devices Market Size Poised for USD 7.2 billion Milestone by 2030 At a CAGR of 6.5%
Audiology Devices Market Size Poised for USD 7.2 billion Milestone by 2030 At a โ€ฆ
Audiology devices are tools used in the field of audiology to diagnose, treat, and manage hearing and balance disorders. These devices can include hearing aids, cochlear implants, bone-anchored hearing systems, tinnitus masking devices, auditory brainstem implants, and hearing protection devices. the report provides comprehensive information on the market trends, including insights on the top segments and key investment opportunities. The report also likely includes a detailed analysis of the valueโ€ฆ
3D Cell Culture Market Size (USD 8.3 Billion by 2031): Growth Prospects, Innovations, and Competitive Landscape to 2032
3D Cell Culture Market Size (USD 8.3 Billion by 2031): Growth Prospects, Innovat โ€ฆ
Allied Market Research has published a study report with the title 3D Cell Culture Market Size was Valued at USD 1.6 billion in 2021 and is estimated to surpass around USD 8.3 billion by 2031, registering revenue CAGR of 18.2% from 2022 to 2031. What is 3D cell culture? 3D cell culture refers to a method of growing cells in three-dimensional environments that more closely mimic the in vivo conditions found inโ€ฆ
Enteric Disease Testing Market Sets New Record, Projected at USD 5.3 billion by 2032 | CAGR of 3.3%
Enteric Disease Testing Market Sets New Record, Projected at USD 5.3 billion by โ€ฆ
Allied Market Research published a report, titled, "Enteric Disease Testing Market By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End User (Hospital Laboratories, Pharmaceutical, and Biotechnology Companies, Academic and Research Institutes): Global Opportunity Analysis And Industry Forecast, 2022-2032". According to the report, the global enteric disease testing industry generated $3.8 billion in 2022โ€ฆ

All 5 Releases


More Releases for Duchenne

Duchenne Muscular Dystrophy (DMD) Market Growth in 2034
Market Overview The Duchenne Muscular Dystrophy (DMD) Market is expanding rapidly as advances in genetic medicine, exon-skipping therapies, gene therapy platforms, and improved diagnostic capabilities reshape treatment options for this severe, progressive neuromuscular disorder. DMD is caused by mutations in the dystrophin gene, leading to muscle degeneration beginning in early childhood. Growing awareness among clinicians and caregivers, widespread adoption of next-generation sequencing (NGS), and increasing availability of disease-modifying therapies have significantly strengthenedโ€ฆ
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr โ€ฆ
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025? The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in theโ€ฆ
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B โ€ฆ
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be? The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives. The Duchenne muscular dystrophy (DMD) therapeuticsโ€ฆ
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. โ€ฆ
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein inโ€ฆ
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy marketโ€ฆ